-Reuters
Eli Lilly And Co Says Lebrikizumab Combined With Topical Corticosteroids Showed Significant Improvements In Disease Severity For Atopic Dermatitis; Says Trial That Met All Primary And Key Secondary Endpoints
At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75
